Department of Anesthesiology, Cancer Institute and Hospital, National Cancer Center, Chinese Academy of Medical Sciences, Peking Union Medical College, No. 17 Panjiayuannanli Road, Chaoyang District, Beijing, 100021, China.
J Anesth. 2014 Jun;28(3):325-33. doi: 10.1007/s00540-013-1732-3. Epub 2013 Oct 31.
Opioids are commonly used for general anesthesia, but reflex cough can occur after an intravenous injection. We have performed a meta-analysis of randomized controlled trials (RCTs) that evaluated the effectiveness and safety of prophylactic lidocaine administered intravenously (IV) on opioid-induced cough (OIC) during induction in patients undergoing general anesthesia.
We searched three bibliographic databases (PubMed, Embase, and the Cochrane Central Register of Controlled Trials) to identify studies meeting a priori inclusion criteria and also conducted a secondary reference review. The information used to calculate the relationship between lidocaine prophylaxis and the risk and severity of OIC was extracted by two principal investigators, respectively.
Six RCTs with a total of 1,740 participants were included in this meta-analysis. Overall, prophylactic lidocaine administered IV reduced both the risk of OIC [pooled risk ratio (RR) 0.471; 95 % confidence interval (CI) 0.355-0.625; P = 0.074; heterogeneity test, I (2) = 50.3 %] and its severity (weighed mean difference -0.316; 95 % CI -0.480 to -0.151; P = 0.038; heterogeneity test, I (2) = 60.5 %). Sub-group analysis indicated a significant reduction in the incidence of both fentanyl-induced cough (FIC) and remifentanil-induced cough (RIC), but it appeared that lidocaine only alleviated the severity of FIC. Further sub-group analysis indicated that the lowest effect dose of lidocaine for preventing the prevalence of OIC was 0.5 mg/kg. No severe adverse effects were reported.
Our meta-analysis establishes the effectiveness of prophylactic lidocaine administered IV for the prevention of OIC during induction. The lowest effective dose of lidocaine on the risk of OIC appeared to be 0.5 mg/kg.
阿片类药物常用于全身麻醉,但静脉注射后会出现反射性咳嗽。我们对评估全身麻醉诱导期间静脉注射预防性利多卡因对阿片类药物诱导咳嗽(OIC)的有效性和安全性的随机对照试验(RCT)进行了荟萃分析。
我们检索了三个文献数据库(PubMed、Embase 和 Cochrane 对照试验中心注册库),以确定符合预先纳入标准的研究,并进行了二次参考文献审查。两位主要研究者分别提取了用于计算利多卡因预防与 OIC 风险和严重程度之间关系的信息。
本荟萃分析共纳入了 6 项 RCT,共 1740 名参与者。总体而言,静脉注射预防性利多卡因可降低 OIC 的风险[汇总风险比(RR)0.471;95%置信区间(CI)0.355-0.625;P=0.074;异质性检验,I(2)=50.3%]及其严重程度(加权均数差-0.316;95%CI-0.480 至-0.151;P=0.038;异质性检验,I(2)=60.5%)。亚组分析表明,芬太尼诱导咳嗽(FIC)和瑞芬太尼诱导咳嗽(RIC)的发生率均显著降低,但似乎利多卡因仅缓解了 FIC 的严重程度。进一步的亚组分析表明,预防 OIC 发生的利多卡因最低有效剂量为 0.5mg/kg。未报告严重不良事件。
我们的荟萃分析确立了静脉注射预防性利多卡因预防诱导期间 OIC 的有效性。预防 OIC 风险的利多卡因最低有效剂量似乎为 0.5mg/kg。